medcelerator · clinician one-pager
New Daily Pill for Chronic Weight Management in Adults
Foundayo (orforglipron) for chronic weight management
FDA Approved · United States, Canada, United Kingdom · September 4, 2026
Condition: Obesity
Who this is for
FDA labelled oral orforglipron for chronic weight management in adults. UK MHRA also labelled weight management and type 2 diabetes — those lines stay separate. Health Canada under review. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States and the United Kingdom, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In Canada, authorisation is not confirmed; see Possible routes below if any are listed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
United Kingdom · Prescription
UK prescription (MHRA-authorised)
https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes
United States · Recruiting clinical trial
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Tests this treatment. Orforglipron in adults with overweight at risk of complications (phase 3).
https://clinicaltrials.gov/study/NCT07794579
United States, Canada · Recruiting clinical trial
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Combination or different setting. Tests orforglipron for stress urinary incontinence in women with obesity (phase 3).
https://clinicaltrials.gov/study/NCT07202884
United States, United Kingdom · Recruiting clinical trial
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Combination or different setting. Children 6-17 with obesity; the label is adults (phase 3).
https://clinicaltrials.gov/study/NCT06672549
Search all trials on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=obesity&intr=orforglipron&aggFilters=status:rec
Search Health Canada's Clinical Trials Search Portal: https://clinical-trials-search.canada.ca/en/search?search_api_fulltext=orforglipron
Possible routes (not confirmed)
Canada · Health Canada Special Access Programme (SAP) · Applicability unknown
Health Canada Special Access Programme (manufacturer must agree)
SAP here depends on the manufacturer agreeing to supply; no confirmation for this drug.
https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html
General resources for further research
Canadian Clinical Trial Search Portal (Health Canada)
Health Canada's public search of the drug and biologic clinical trials it has authorised in Canada (phase 1 to 3, since April 2013). Search by condition, drug, or trial status and see where trials are running. It replaced the Health Canada Clinical Trials Database in July 2026. A listing is not enrolment, and Health Canada does not recruit patients: ask your clinician and contact the trial sponsor.
https://clinical-trials-search.canada.ca/en/home
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/foundayo-orforglipron